HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional)
ID: 360439Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360439
Timeline
    Description

    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials," aimed at establishing a Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) focused on heart failure with preserved ejection fraction (HFpEF). The initiative seeks to coordinate precision clinical trial activities, including master protocol development, project management, and recruitment oversight, while the CCs will be responsible for recruiting and retaining heart failure patients and conducting deep phenotyping protocols. This program is crucial for advancing personalized treatment approaches in heart failure, and while applications are not currently being solicited, interested parties are encouraged to prepare collaborative proposals ahead of the estimated synopsis posting on October 15, 2025, with a projected award date of May 1, 2026. For further inquiries, applicants can contact the HeartShare Team via email at nhlbiheartshare@mail.nih.gov.

    Point(s) of Contact
    Division of Cardiovascular Sciences, HeartShare Team
    Please contact via e-mail.
    nhlbiheartshare@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Single Source: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a single-source cooperative agreement opportunity titled "HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional)." This funding aims to renew the Data Translation Center (DTC) for the NHLBI's ongoing HeartShare program, focusing on coordinating projects that support patients with heart failure with preserved ejection fraction (HFpEF) and analyzing existing data from NIH cohorts and trials. This non-competitive funding opportunity is exclusively available to Northwestern University, with an estimated synopsis posting date of October 15, 2025, and a projected award date of May 1, 2026. Interested applicants can reach out to the HeartShare Team at nhlbiheartshare@mail.nih.gov for further information.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to solicit applications for the establishment of a Clinical Coordinating Center (CCC) dedicated to multi-site investigator-initiated clinical trials, including efficacy, comparative effectiveness, and implementation research. The objective of this opportunity is to develop a comprehensive scientific and operational plan for the clinical trials that align with the research mission of the National Heart, Lung, and Blood Institute (NHLBI) and meet the NIH definition of a clinical trial. This cooperative agreement will follow a bi-phasic, milestone-driven award mechanism and requires the submission of both a CCC application and a collaborating Data Coordinating Center (DCC) application by the same deadline. Interested applicants can reach out to Dr. Yves Rosenberg at rosenbey@nhlbi.nih.gov or call 301-435-0550 for further information. The estimated synopsis post date is July 11, 2025, with applications expected to close on October 13, 2025, and awards anticipated by May 1, 2026.
    Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers, aimed at expanding an international cardiac surgery research platform. This initiative will focus on integrating various areas of research, including interventional cardiology, peri-operative care, dissemination and implementation science, circadian medicine, and mechanistic science, to enhance the health outcomes of adults with cardiovascular disease and related neurologic complications. The platform will also serve as a training ground for future clinical trialists and implementation researchers, fostering collaboration among academia, small businesses, and other stakeholders. While applications are not currently being solicited, interested parties are encouraged to prepare for future submissions, with the estimated synopsis post date set for February 2, 2026, and the estimated project start date anticipated for January 1, 2027. For further inquiries, potential applicants can contact Dr. Kathleen Fenton at kathleen.fenton@nih.gov or by phone at 301-221-7865.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at supporting Phase I clinical trials for therapeutic and diagnostic interventions related to heart, lung, blood, and sleep (HLBS) disorders. This initiative seeks to accelerate the development of clinical interventions by funding investigator-initiated studies that demonstrate potential advancements in HLBS health, with a focus on ensuring that applicants are prepared to initiate trials promptly after receiving funding. The funding is capped at $1.5 million per year for a project period of up to three years, contingent on satisfactory progress and milestone completion, with applications opening on January 3, 2025, and the first due date set for February 3, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-025.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders," aimed at supporting investigator-initiated Phase I clinical trials for heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This grant (R61/R33) facilitates funding for essential preclinical activities and the execution of clinical trials, structured in two phases: the R61 phase focuses on preparatory tasks, while the R33 phase involves the actual trial conduct, guided by specific milestones. This initiative is crucial for advancing research that addresses significant health challenges associated with HLBS disorders. Interested applicants can submit proposals starting January 3, 2025, with a maximum project period of five years, and should direct inquiries to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-026.html.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Trial Pilot Studies (R34 Clinical Trial Optional) through the National Heart, Lung, and Blood Institute (NHLBI). This initiative aims to support research that provides essential information for the design of future Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders, requiring applicants to demonstrate the scientific necessity and sufficiency of their proposed studies. The NHLBI emphasizes inclusivity by mandating a Plan for Enhancing Diverse Perspectives (PEDP) to enhance the project's scientific merit, with a budget of up to $450,000 in direct costs available over a maximum project period of three years. Interested applicants should note that the application period opens on January 16, 2025, and the final submission deadline is January 7, 2027; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the establishment of a Clinical Coordinating Center aimed at generating a Precision Medicine Intergenerational Resource for studying Factor VIII immunogenicity in severe Hemophilia A. This initiative will utilize a UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement, providing a total funding ceiling of $1,338,000 over a potential seven-year period, contingent upon the successful completion of defined milestones. The project is critical for advancing research in hemophilia treatment and will involve a collaborative effort with a companion award for a Biospecimen and Data Resource Center. Interested applicants can reach out to Iman K. Martin, PhD, MPH, MS at iman.martin@nih.gov or call 301-435-0065 for further details, with the estimated synopsis post date having been set for March 2, 2020.